ArmaGen closes $17M Series A financing ArmaGen Technologies, Inc. Today announced the closing of a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead trader is usually Boehringer Ingelheim Venture Fund, joined up with by Shire plc, Takeda Ventures, Inc caverta 100 ., and Mitsui & Co. Global Investment, Inc. This funding permits expansion of existing procedures, and the clinical development of potentially first-in-course biopharmaceuticals targeting illnesses of the central anxious program , which are engineered to penetrate the blood-brain barrier . This is the first time such a different group from the pharmaceutical industry has get together to financing technology in the blood-mind barrier.